LY3461767 for Heart Failure

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center, Kanazawa Ward,Yokohama, JapanHeart FailureLY3461767 - Drug
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it is safe and how well it works in people with heart failure.

Eligible Conditions
  • Heart Failure with Reduced Ejection Fraction (HFrEF)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline through Day 90

Baseline through Day 90
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Hour 48
PK: Maximum Concentration (Cmax) of LY3461767
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3461767

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

LY3461767
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

50 Total Participants · 2 Treatment Groups

Primary Treatment: LY3461767 · Has Placebo Group · Phase 1

LY3461767
Drug
Experimental Group · 1 Intervention: LY3461767 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline through day 90

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,482 Previous Clinical Trials
3,143,096 Total Patients Enrolled
13 Trials studying Heart Failure
20,333 Patients Enrolled for Heart Failure
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,268 Previous Clinical Trials
371,247 Total Patients Enrolled
2 Trials studying Heart Failure
1,132 Patients Enrolled for Heart Failure

Eligibility Criteria

Age 18 - 80 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must weigh less than or equal to 45 kilograms per square meter based on your height.

Frequently Asked Questions

Am I eligible to join this research protocol?

"Eligibility requirements for this trial mandates that applicants are between 18-80 years of age and have a diagnosis of heart failure. Around 50 patients will be accepted into the study." - Anonymous Online Contributor

Unverified Answer

How many participants are participating in the trial?

"This trial necessitates the enrolment of 50 willing participants that satisfy established criteria. Potential subjects can sign up from Sentara Healthcare in Norfolk, Virginia and Henry Ford Hospital in Detroit, Michigan." - Anonymous Online Contributor

Unverified Answer

Are participants over 45 years old eligible for this research trial?

"Eligibility requirements for this clinical trial state that participants must be between 18 and 80 years old. Separately, there are 22 trials available to minors and 690 for seniors over 65." - Anonymous Online Contributor

Unverified Answer

Are there still opportunities for individuals to enroll in this research endeavor?

"Correct. As per the clinicaltrials.gov records, this medical study is currently recruiting patients. The trial was first initiated on June 1st 2021 and recently updated as of July 18th 2022; 50 individuals will be needed from 4 different sites for participation in the experiment." - Anonymous Online Contributor

Unverified Answer

How many locations are hosting this clinical investigation?

"This research endeavor is being conducted at four separate sites, such as Sentara Healthcare in Norfolk and the Henry Ford Hospital in Detroit. Additionally, University of North Carolina's Division of Cardiology in Chapel Hill has been included along with 4 other locations." - Anonymous Online Contributor

Unverified Answer

What type of adverse reactions have been associated with LY3461767?

"Given the limited safety data and efficacy proof, our team at Power conservatively rated LY3461767 with a score of 1." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.